Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Bayer HealthCare AG
Femme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
Study of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus in subjects with bone predominant HER2 negative hormone receptor positive metastatic breast cancer. Estudio de dicloruro de radio-223 en combinación con exemestano y everolimús frente a placebo en combinación con exemestano y everolimús en pacientes con cáncer de mama metastásico predominante en hueso, negativo para HER2 y positivo para los receptores hormonales
The objective of this study is to assess efficacy and safety of radium 223 dichloride in combination with exemestane and everolimus in subjects with human epidermal growth factor receptor 2 (HER2) neg...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
MAGELLaN - Multicenter, rAndomized, parallel Group Efficacy and safety study for the prevention of venous thromboembolism in hospitalized medically iLL patients comparing rivaroxabAN with enoxaparin
The objective of this study is to demonstrate (1) the superior efficacy of VTE prophylaxis with oral rivaroxaban 10 mg once daily administered for 35 +/- 4 days to SC enoxaparin 40 mg once daily (OD) ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination with Aspirin Alone or with Aspirin and a Thienopyridine in Subjects with Acute Coronary Syndromes (39039039ACS2001) The ATLAS ACS TIMI 46 Trial (Anti-Xa Therapy to Lower cardiovascular events in addition to Aspirin with or without thienopyridine therapy in Subjects with Acute Coronary Syndrome)
Stage 1 Dose Escalation The primary objective of Stage 1 (Dose Escalation) of this study is to evaluate the safety of rivaroxaban in subjects with recent acute coronary syndrome (ACS) (including ST-se...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients with Advanced Renal Cell Carcinoma
The objective of this study is to make BAY 43-9006 available for patients with advanced RCC, who failed prior systemic therapy for advanced disease (i. e., require second line treatment), and who do n...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
A study, in patients with prostate cancer that has spread to the bones, investigating the efficacy of radium-223 dichloride given as a 50kBq/kg dose every four weeks or a 80kBq/kg dose every four weeks in radium-223 dichloride naive patients for six doses or as a 50kBq/kg every four weeks to patients who have already been treated with a course of six doses of radium-223 dichloride
• To evaluate efficacy as measured by symptomatic skeletal event-free survival (SSE-FS) of radium-223 dichloride 50 kBq/kg every 28 days for up to 6 doses compared to radium-223 dichloride 80 kBq/kg ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
LCS12 adolescent study
The primary objective is to assess the safety of low-dose levonorgestrel (LNG) (12μg/24h, initial in vitro release rate), delivered locally by an intrauterine contraceptive system in adolescents over ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
A study investigating the safety of radium-223 dichloride, given as a 50kBq/kg dose every four weeks to patients with castration-resistant prostate cancer that has spread to bone, who have already been treated with a course of six doses of radium-223 dichloride 50kBq/kg every four weeks. Estudio para investigar la seguridad de dicloruro de radio 223, con una dosis de 50 kBq/kg cada cuatro semanas a pacientes con cáncer de próstata resistente a la castración que se ha propagado al hueso, y que ya habían sido tratados con ciclo de seis dosis de dicloruro de radio 223 de 50 kBq/kg cada cuatro semanas
To assess the safety of re-treatment with up to 6 doses of radium-223 dichloride 50 kBq/kg given every 4 weeks in subjects with castration-resistant prostate cancer (CRPC) with bone metastases who rec...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
Estudio fase II no controlado, abierto en pacientes con adenocarcinoma metastásico de colon o recto, que están recibiendo quimioterapia de primera línea con mFOLFOX6 (oxaliplatino/acido folínico/5-fluorouracilo [5-FU]) en combinación con regorafenib (An uncontrolled, open-label, phase II study in subjects with metastatic adenocarcinoma of the colon or rectum who are receiving first line chemotherapy with mFOLFOX6 (oxaliplatin/ folinic acid/5-fluorouracil [5-FU]) in combination with regorafenib)
Tasa de respuesta objetiva (TRO) evaluada centralmente
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis ODIXa-DVT A prospective, randomized, multinational, multicenter, partially blinded, parallel-group, open-label active comparator controlled phase II Dose Finding and Proof of Principle Trial
The objectives of this Phase II dose finding trial are to assess the efficacy and safety of BAY 59-7939 for the treatment of acute symptomatic proximal deep vein thrombosis (objectively confirmed by c...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
A Phase III randomized, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma ** Amendment 1 Version 2.0 of December 13th 2004 is also included
Main objective: To evaluate safety, efficacy, PRO, and population PK of sorafenib versus placebo in patients with advanced HCC. Primary efficacy objectives: • Efficacy in patients treated with soraf...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
5
6
7
8
9
10
11
12
13
14
Suivant